IMP3 signatures of fallopian tube: a risk for pelvic serous cancers
Affiliation
Department of Obstetrics and Gynecology, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA
Department of Obstetrics and Gynecology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, China
Department of Pathology, Shanxi Medical University, Shanxi, China
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China
Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
Department of Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USA
Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ, USA
Department of Pathology, University of Massachusetts Medical Center, Worcester, MA, USA
Issue Date
2014
Metadata
Show full item recordPublisher
BioMed CentralCitation
Wang et al. Journal of Hematology & Oncology 2014, 7:49 http://www.jhoonline.org/content/1/1/49Journal
Journal of Hematology & OncologyRights
© 2014 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).Collection Information
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.Abstract
BACKGROUND:Recent advances suggest fallopian tube as the main cellular source for women's pelvic serous carcinoma (PSC). In addition to TP53 mutations, many other genetic changes are involved in pelvic serous carcinogenesis. IMP3 is an oncofetal protein which has recently been observed to be overexpressed in benign-looking tubal epithelia. Such findings prompted us to examine the relationship between IMP3 over-expression, patient age and the likelihood of development of PSC.METHODS:Fallopian tubes from three groups (low-risk, high-risk, and PSC) of patients with matched ages were studied. Age was recorded in 10years intervals ranging from age 20 to older than 80. The number of IMP3 signatures (defined by 10 or more tubal secretory cells stained positively and continuously in benign appearing tubal mucosa) from both tubal fimbria and ampulla segments was measured. The data was analyzed by standard contingency table and Poisson distribution methods after age adjustment. IMP3 overexpression was also examined in serous tubal intraepithelial carcinoma and PSC.RESULTS:The positive IMP3-stained cells are mainly tubal secretory cells. The absolute number of tubal IMP3 signatures increased significantly within each age group. Age remained a significant risk factor for serous neoplasia after age adjustment. IMP3 signatures were more frequent in the patients of both high-risk and PSC groups. The presence of IMP3 signatures in tubal mucosa was significantly associated with tubal or pelvic serous carcinogenesis (p<0.001).CONCLUSIONS:The findings suggest that tubal secretory cells with IMP3 signatures showing growth advantage could potentially serve as a latent precancer biomarker for tubal or pelvic serous carcinomas in women.EISSN
1756-8722Version
Final published versionAdditional Links
http://www.jhoonline.org/content/7/1/49ae974a485f413a2113503eed53cd6c53
10.1186/s13045-014-0049-5
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2014 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).

